Acquired purpura fulminans is a rare, life‑threatening blood clotting disorder that causes sudden skin bruising and tissue damage. It often begins quickly with fever or severe infection and rapidly spreading dark patches on the skin. People with acquired purpura fulminans may feel very ill, and doctors may see low blood pressure, clotting problems, and signs of organ stress. Mortality can be high without urgent care, but early treatment in intensive care and antibiotics can save lives. Treatment usually includes antibiotics, blood products, protein C replacement, and surgery for damaged tissue when needed.
Overview
Acquired purpura fulminansSymptoms
Acquired purpura fulminans causes sudden purple skin spots and fast‑spreading bruises that may blister or turn black. Early symptoms of acquired purpura fulminans include fever, feeling unwell, and limb pain. People may develop bleeding, confusion, low blood pressure, or shock.
Outlook and prognosis
Acquired purpura fulminans is a medical emergency, but prompt treatment in intensive care can be lifesaving. Recovery depends on how quickly care begins, the infection or trigger involved, and organ impact. Some people need skin grafts or rehabilitation afterward.
Causes and risk factors
Acquired purpura fulminans usually follows severe infection or sepsis—classically meningococcal, streptococcal, or varicella—with widespread clotting and low protein C/S. Risks rise with recent viral or bacterial illness, immune suppression, liver failure, major trauma or surgery, and lack of vaccination.
Genetic influences
Genetics play little direct role in acquired purpura fulminans; it’s typically triggered by infection, severe illness, or anticoagulant issues. Rare inherited thrombophilias may modify risk or severity. Genetic testing is generally unnecessary; evaluation targets acquired causes and protein C status.
Diagnosis
Diagnosis of Acquired purpura fulminans relies on the sudden skin findings and systemic illness, supported by urgent labs showing disseminated clotting: prolonged PT/INR and aPTT, low platelets and fibrinogen, high D‑dimer. Blood cultures and sometimes skin biopsy help confirmation.
Treatment and drugs
Treatment for acquired purpura fulminans focuses on urgent supportive care, antibiotics if infection is suspected, and careful blood product replacement. Doctors often use plasma and protein C concentrates, plus anticoagulation when safe, to stabilize clotting. Intensive wound care and surgery may be needed for damaged skin.
Symptoms
It can start suddenly with severe skin pain and a bruise-like rash that spreads within hours, while clotting and bleeding fall out of balance. Early on, this might look like a bad flu with fever and chills, plus new, very tender purple spots on the legs or arms. People often ask about early symptoms of Acquired purpura fulminans; these include feeling acutely unwell, rapidly expanding dark patches or blisters on the skin, and pain that seems out of proportion to what you see. Because the illness can escalate quickly, seek emergency care if these symptoms appear together.
Sudden, tender, bruise-like spots or patches can appear, often on the legs or arms. They may feel warm or very sore to the touch.
The rash can enlarge quickly over minutes to hours. New dark patches may pop up in other areas. Edges can look sharply outlined or blotchy.
Clear or bloody blisters can form on top of the dark areas. The skin can turn very dark or black as tissue is injured. In Acquired purpura fulminans, this can progress to open sores.
Pain can be intense and out of proportion to what the skin first looks like. Touch, movement, or clothing rubbing may make it worse.
How people usually first notice Acquired purpura fulminans?
People often first notice purpura fulminans as a sudden, severe illness with high fever, feeling very unwell, and rapidly spreading dark-purple skin spots or bruises that can look like painful patches or blisters. These skin changes usually start on the legs or trunk and can progress within hours, sometimes alongside cold hands and feet, confusion, or signs of shock, which are medical emergencies. In many cases, the first signs of purpura fulminans follow a recent infection—especially meningococcal or other severe bacterial infections—prompting urgent evaluation and treatment.
Types of Acquired purpura fulminans
Acquired purpura fulminans is a rare, rapidly evolving blood-clotting emergency. Even within this condition, there are a few recognized clinical variants that start for different reasons and can look a bit different in timing and triggers. Clinicians often describe them in these categories: infection-related, antibody-mediated (immune), and post-illness or idiopathic. Knowing the types of acquired purpura fulminans can help explain why symptoms begin and how they may progress.
Infection-associated
This type follows a severe infection, often bacterial, and symptoms can escalate within hours. Skin may develop painful dark patches that spread quickly as tiny vessels clot. Fever, low blood pressure, and signs of sepsis often accompany the skin changes.
Autoimmune/antibody-mediated
Here, the immune system creates antibodies that disable natural anticoagulants, especially protein C, leading to sudden clotting in small vessels. It may occur after certain illnesses, surgery, or rarely after medications. Skin findings can resemble the infection-associated form but without active sepsis.
Post-infectious (idiopathic)
This variant appears days to weeks after a viral or bacterial illness when the acute infection has passed. People may have low levels of protein C or S without ongoing infection, and skin lesions can develop more gradually. Symptoms may be slightly less abrupt than the infection-associated type, but they can still become severe.
What genetics can tell you about symptoms
Some rare inherited clotting protein changes, like protein C or protein S deficiencies, can trigger acquired purpura fulminans after infections by tipping blood toward widespread clots. This can lead to sudden bruising, purple-black skin patches, severe pain, fever, and tissue damage.
Causes and risk factors
Acquired purpura fulminans often starts after a severe infection or sepsis.
The infection can cause a sudden clotting imbalance with very low levels of natural clot regulators like protein C or protein S.
Risk is higher with invasive bacteria, chickenpox or shingles, shock, major surgery or trauma, and liver failure.
Weakened immunity, not having a spleen, heavy alcohol use that damages the liver, and rare inherited clotting tendencies are additional risk factors for acquired purpura fulminans.
It’s rarely just one factor, and the mix matters.
Environmental and biological risk factors
Acquired purpura fulminans is a rare, fast-moving blood-clotting emergency that usually follows a severe infection. Knowing the early symptoms of acquired purpura fulminans can help, but understanding what increases risk often prompts faster care. Doctors often group risks into internal (biological) and external (environmental). Here are key environmental and biological factors linked to higher risk.
A bloodstream infection with meningococcal bacteria can rapidly trigger widespread clotting and skin damage. This is one of the most common infectious triggers of acquired purpura fulminans. Prompt antibiotics and critical care lower risk.
Severe pneumococcal bloodstream infection can set off the same clotting cascade that injures skin and organs. It markedly raises the chance of acquired purpura fulminans. Urgent treatment can blunt the process.
After chickenpox (varicella), some people develop immune changes that reduce natural clot-control proteins. This post-infectious state can precipitate acquired purpura fulminans, especially in children. Watch for sudden bruising, dark skin patches, or severe pain.
Invasive group A streptococcal disease or other overwhelming bacterial sepsis can also drive this syndrome. The shared pathway is overwhelming inflammation and clotting within small vessels. This can escalate quickly without urgent care.
Genetic risk factors
Your genetic makeup can influence the balance of the body’s anti-clotting systems involved in Acquired purpura fulminans. Certain inherited blood-clotting traits can raise the chance that this rare emergency develops or becomes more severe. Carrying a genetic change doesn’t guarantee the condition will appear. Understanding the genetic risk factors for Acquired purpura fulminans can help families discuss testing and plan care when a known thrombophilia runs in the family.
Protein C deficiency: Having a lower-than-usual baseline of protein C reduces your natural brake on clotting. In Acquired purpura fulminans, this can make the rapid loss of anticoagulant protection more severe.
Protein S deficiency: Protein S helps protein C work; if levels are low from birth, the system starts with less reserve. This inherited change may increase the likelihood or severity of Acquired purpura fulminans.
Factor V Leiden: This common variant makes factor V less responsive to activated protein C. The reduced sensitivity can tip the balance toward clotting under stress.
Prothrombin G20210A: This change raises prothrombin levels, which can prime the blood for clot formation. People with this variant have a higher tendency to form clots, which may contribute to fulminant skin clotting.
Antithrombin deficiency: Lower antithrombin limits the body’s ability to neutralize clotting enzymes. This inherited shortfall can intensify widespread clotting in the microcirculation.
Lifestyle risk factors
Acquired purpura fulminans is usually triggered by overwhelming infection or disruptions in the body’s clotting balance, and certain behaviors can raise or lower that risk. Below are lifestyle risk factors for acquired purpura fulminans that influence infection risk, anticoagulation control, and the body’s ability to regulate clotting. These factors do not cause the condition by themselves, but they can shape how likely a severe trigger occurs or how quickly it escalates.
Skipping vaccines like meningococcal and varicella increases chances of severe infections that can precipitate acquired purpura fulminans. Staying up to date lowers the risk of infection-driven clotting collapse.
Nonsterile injection practices raise the risk of invasive bacterial infections and sepsis that can trigger purpura fulminans. Accessing harm-reduction services and sterile supplies reduces infection risk.
Heavy alcohol intake weakens immune defenses and impairs liver production of natural anticoagulants like protein C, amplifying coagulopathy during severe infections. Cutting back can lower the chance that an infection progresses to purpura fulminans.
Skipped doses, sudden binge drinking, or large swings in vitamin K intake destabilize anticoagulation and, rarely, can contribute to warfarin-associated purpura fulminans. Consistent dosing and monitoring help keep clotting in a safer range.
Risk prevention
The most effective ways to lower risk focus on avoiding severe infections and acting fast if they happen. Prevention works best when combined with regular check-ups. Vaccines, quick treatment for fevers or rashes, and knowing when to seek emergency care can make a real difference for people at risk of acquired purpura fulminans. Keeping liver health on track and sharing key history with your care team also helps reduce complications.
Routine vaccines against meningococcal disease, pneumococcus, influenza, and chickenpox (varicella) lower the chance of severe infections that can trigger acquired purpura fulminans. Ask about boosters before college dorms, military service, travel, or outbreak situations.
See a clinician promptly for high fever, severe sore throat, a new widespread rash, or illness that worsens quickly. Early antibiotics or antivirals can reduce the chain reaction that leads to clotting problems.
Go to emergency care for symptoms like fever or chills, very fast breathing or heart rate, confusion, extreme weakness, or skin that looks blotchy or very pale. Rapid treatment of sepsis can prevent the severe clotting seen in acquired purpura fulminans.
Get urgent care for rapidly spreading purple spots, severe leg or arm pain with swelling, or skin that turns cold and dusky. Fast evaluation can limit tissue damage and complications.
Transmission
Acquired purpura fulminans is not contagious or inherited, so it cannot be passed from person to person. It usually develops as a severe reaction to another illness—most often a serious bacterial infection such as meningococcal disease, or less commonly a viral infection like chickenpox—so any risk of spread comes from the infection itself, not from acquired purpura fulminans. Those infections can spread through close contact, coughs and sneezes (respiratory droplets), or direct contact with fluid from chickenpox blisters, which is why prompt medical care and following public health advice for close contacts matters. If you’re wondering how acquired purpura fulminans is transmitted, the short answer is that it isn’t; reducing risk depends on preventing and treating the trigger infection.
When to test your genes
Consider genetic testing if you’ve had unexplained, severe blood clots or purpura fulminans—especially in childhood—or if close relatives had early clotting disorders. Testing for inherited thrombophilias (like protein C, protein S, or antithrombin deficiencies) can guide prevention, dosing, and family screening. If infection triggered your episode, genetics still matter for recurrence risk.
Diagnosis
Sudden, painful dark-purple skin patches with fever or signs of bleeding usually trigger urgent evaluation for Acquired purpura fulminans. Doctors usually begin with a focused exam and lab tests to check how your blood is clotting and whether infection is present. Understanding how Acquired purpura fulminans is diagnosed can help you know what to expect. Because this condition can move quickly, testing often happens at the same time as emergency treatment.
Clinicians look for sharply bordered purple skin areas, blisters, and skin that feels cool or firm, which can signal tissue injury. They also check vital signs and symptoms suggesting widespread infection or shock.
Your team asks about recent infections, chickenpox or shingles, surgery, childbirth, new medicines, or severe illness. These details help pinpoint triggers linked to acquired purpura fulminans.
A complete blood count checks platelets and anemia, and chemistry tests assess kidney and liver function. Abnormal results can support a picture of widespread clotting and bleeding.
Tests such as prothrombin time, activated partial thromboplastin time, fibrinogen, and D‑dimer help show if disseminated intravascular coagulation is present. A pattern of low fibrinogen, low platelets, and high D‑dimer is common in this condition.
Stages of Acquired purpura fulminans
Acquired purpura fulminans does not have defined progression stages. It tends to appear suddenly and can worsen over hours, often during a severe infection or a widespread clotting problem, so the course varies based on how quickly the trigger is found and treated. Doctors diagnose it based on early symptoms of acquired purpura fulminans—painful purplish skin patches that spread quickly, fever, and signs of sepsis—together with exam findings and urgent blood tests that show a clotting imbalance (low platelets, raised D‑dimer, low fibrinogen, prolonged PT/INR), and sometimes low protein C. Different tests may be suggested to help find the underlying trigger, like blood cultures for infection and imaging if needed.
Outlook and prognosis
Bleeding into the skin can start suddenly with acquired purpura fulminans, often after a severe infection or a big hit to the immune system. Skin may darken in patches that feel painful or warm, and fever or confusion can follow quickly. Early care can make a real difference, especially when treatment begins within hours rather than days. Doctors call this the prognosis—a medical word for likely outcomes.
The outlook for acquired purpura fulminans depends on how fast it’s recognized, what’s driving it (usually a serious bacterial infection or an immune reaction), and how quickly replacement of missing clotting regulators like protein C is started. In intensive care, survival has improved, but the condition still carries a high short‑term risk; reported hospital mortality ranges roughly from 20% to over 50% in severe, infection‑related cases. Some people experience full recovery of organ function, while others notice lasting effects such as scarring, limb or tissue loss from skin necrosis, and nerve pain. Understanding the prognosis can guide planning and follow‑up, including wound care, physical therapy, and support for mood and sleep as recovery unfolds.
Looking at the long-term picture can be helpful. After the acute phase, most people with acquired purpura fulminans do not have ongoing blood‑clotting problems, but a small number may face recurrent clotting if an underlying trigger persists. Risk of death is concentrated in the first days to weeks, tied to shock, widespread clotting, bleeding, and organ failure; once stabilized, the focus shifts to healing and preventing complications like infection of open wounds. If you’re wondering about early symptoms of acquired purpura fulminans to watch for after a serious infection, sudden painful bruising with fever and rapid worsening is a red flag that needs emergency care. Talk with your doctor about what your personal outlook might look like.
Long-term effects
Acquired purpura fulminans is a medical emergency that can leave lasting effects after the crisis passes. Long-term effects vary widely, and depend on how severe the skin, blood vessel, and organ damage was during the acute illness. Early symptoms of acquired purpura fulminans may appear suddenly, but long-term outcomes mostly reflect the extent of skin, muscle, and organ injury during the acute phase. Recovery often involves multiple surgeries and rehabilitation, and some live with permanent changes in appearance or function.
Thick scars and tight bands of tissue can form where the skin was damaged. These contractures may limit movement of joints and affect daily tasks.
Severe circulation loss can lead to amputations of fingers, toes, or limbs. This can change balance and strength and may require long-term rehabilitation.
Some live with ongoing pain, burning, or cold sensitivity in healed areas after acquired purpura fulminans. Pain may flare with activity or weather changes.
Numbness, tingling, or weakness can follow tissue injury and surgeries. Fine motor skills or grip strength may be reduced.
How is it to live with Acquired purpura fulminans?
Living with acquired purpura fulminans can feel like life suddenly splits into “before” and “after,” because the illness often arrives fast and demands intensive care, surgeries for damaged skin, and a long recovery. Day to day, people may face pain from skin grafts or ulcers, limited mobility while wounds heal, fatigue, and the emotional weight of scars and uncertainty about clotting risks or infections that could trigger relapse. Follow-up visits, anticoagulation or replacement therapies when indicated, careful skin care, and infection vigilance become part of the routine, and returning to work or school may require gradual steps and accommodations. Partners, family, and friends often take on caregiving roles and may feel worried or overwhelmed at first, but with clear care plans, rehabilitation, and peer support, many find a new rhythm that balances safety with a meaningful, active life.
Treatment and drugs
Acquired purpura fulminans is a medical emergency, so treatment starts right away in an intensive care setting to support breathing, blood pressure, and organ function while stopping the widespread clotting and bleeding. Doctors give targeted therapy to replace missing natural anticoagulants (often protein C concentrate or fresh frozen plasma), treat any trigger such as severe infection with high‑dose intravenous antibiotics, and use vitamin K if levels are low. If clots keep forming, carefully monitored anticoagulation (for example, heparin) may be used, while platelet or red blood cell transfusions address dangerous bleeding and anemia. Surgery may be needed to remove dead tissue or, in severe cases, to manage limb damage, and wound care helps prevent infection. Finding the right therapy can take some time, with the team adjusting treatments as your condition changes hour by hour.
Non-drug treatment
People who develop acquired purpura fulminans usually need urgent hospital care, often in an intensive care unit, to stabilize breathing, blood flow, and skin injuries. Getting help quickly at the first signs or early symptoms of acquired purpura fulminans can improve outcomes and limit tissue damage. Alongside medicines, non-drug therapies focus on protecting organs, caring for damaged skin, and helping you recover function. A coordinated team—critical care, wound specialists, surgeons, therapists, and mental health support—works together to meet day-to-day needs.
Continuous checks of heart rate, blood pressure, oxygen levels, and urine output guide moment-to-moment decisions. This helps the team respond quickly as acquired purpura fulminans can change fast.
IV fluids and careful positioning help maintain circulation and protect organs. Doctors adjust fluids based on your vital signs and lab results.
Extra oxygen or a breathing machine may be used if lungs are stressed. The goal is to keep oxygen levels safe while your body heals.
Dialysis may be needed if the kidneys are overwhelmed. This temporary support helps clear wastes and balance fluids until kidney function improves.
Your genes may have an impact on how drugs work for you
Some medicines for acquired purpura fulminans work differently based on your genes, which can change how you process anticoagulants, antibiotics, and vitamin K–related treatments. Genetic differences may affect dose needs, bleeding or clotting risk, and how quickly you respond.
Pharmacological treatments
Treatment focuses on stopping the infection or trigger, replacing missing clotting proteins, and carefully preventing new clots while controlling bleeding. First-line medications are those doctors usually try first, based on how quickly the condition is progressing and the suspected cause. Because early symptoms of acquired purpura fulminans can worsen within hours, medicines are started urgently in hospital. Your exact plan may shift from day to day as lab results change.
Doctors start IV antibiotics right away if sepsis is suspected. Common choices include ceftriaxone, vancomycin, and piperacillin-tazobactam, then therapy is narrowed once cultures return.
If meningococcal infection is confirmed, ceftriaxone or high-dose penicillin G is used. For other bacteria, the antibiotic is switched to match the specific germ and its sensitivities.
Human protein C (for example, Ceprotin) can replace the depleted natural anticoagulant and may slow skin and tissue damage. It is given intravenously with close monitoring for bleeding and clotting balance.
Plasma infusions provide protein C and other clotting factors that are low in this condition. This can stabilize the blood’s clotting system while other treatments take effect.
Genetic influences
Acquired purpura fulminans is generally not inherited; it most often appears after a severe infection or other major illness that suddenly lowers the body’s natural clot‑preventing proteins, especially protein C. It’s natural to ask whether family history plays a role. For most, family history is not a strong driver of risk, but a rare inherited tendency to form clots—such as being born with low protein C or protein S—can make the reaction to a serious infection more severe. Those inherited problems usually show up in newborns and are considered a different condition (neonatal purpura fulminans), while the acquired type happens later in life after a trigger. Because genetic risk for acquired purpura fulminans is low, genetic testing isn’t routinely needed unless there has been unusual clotting in you or close relatives at a young age. Even when someone carries a clotting tendency, many never develop acquired purpura fulminans without a strong trigger such as a widespread infection.
Is Acquired purpura fulminans genetic?
Genetics play little direct role in acquired purpura fulminans; it’s typically triggered by infection, severe illness, or anticoagulant issues. Rare inherited thrombophilias may modify risk or severity. Genetic testing is generally unnecessary; evaluation targets acquired causes and protein C status.
Pharmacogenetics—how genetics influence drug effects
During hospital care for acquired purpura fulminans, people often receive broad antibiotics, blood products (such as plasma or protein C), and blood thinners to steady clotting and bleeding. While the condition itself isn’t inherited, genetic differences can affect how safely and effectively some of these medicines work. If long-term anticoagulation is needed, genes that influence how your body handles warfarin can change the dose required and the risk of bleeding, so a genetics‑guided dose may be considered. A rare change in mitochondrial DNA can make aminoglycoside antibiotics (such as gentamicin) cause sudden hearing loss; if you or a close relative has had this reaction, your team may choose different antibiotics. In addition, people with G6PD deficiency have a higher risk of red blood cell breakdown with certain antibiotics, and doctors can select safer options when that’s known. Alongside medical history and lab results, genetic testing can help tailor drug choice and dosing during and after treatment for acquired purpura fulminans.
Interactions with other conditions
Acquired purpura fulminans often shows up alongside another serious illness, most commonly a widespread infection such as sepsis, and the two can feed into each other by driving uncontrolled clotting and bleeding. Doctors call it a “comorbidity” when two conditions occur together, and in this case infections like meningococcal disease or chickenpox (varicella) can set off the cascade that leads to skin bruising, tissue damage, and organ strain. Early symptoms of acquired purpura fulminans can be harder to spot when sepsis is present because fever, low blood pressure, and confusion may be blamed on the infection alone. Liver disease can intensify the problem by lowering natural clot‑balancing proteins, while autoimmune clotting disorders like antiphospholipid syndrome and active cancer may tilt the body further toward dangerous clot formation. Certain medicines also matter: starting warfarin during severe protein C deficiency can worsen skin injury, so teams often favor heparin at first and switch later when it’s safer. Close, coordinated care is crucial when acquired purpura fulminans overlaps with these conditions, because treating the trigger and the clotting imbalance together improves outcomes.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described sudden, spreading skin bruises that turned dark and painful, sometimes after a fever or sore throat. Families and communities once noticed patterns: a child recovering from chickenpox, then rapidly worsening purple patches; an adult with severe infection who developed blackened skin areas within hours. Today we recognize this picture as acquired purpura fulminans, a medical emergency linked to overwhelming infection or, less often, a delayed immune reaction after an illness.
First described in the medical literature as a catastrophic form of skin and blood vessel injury during sepsis, early reports focused on the striking skin changes and high risk of shock. Over time, descriptions became more precise, noting the combination of widespread clotting in small vessels, falling platelets, and bleeding into the skin. As medical science evolved, clinicians distinguished acquired purpura fulminans from inherited clotting disorders and from other causes of purple skin lesions by its sudden onset and tight link to severe infection or a recent viral illness.
In the pre-antibiotic era, outbreaks of meningococcal disease and other bacterial infections occasionally led to clusters of these cases, often in children and young adults. With antibiotics and intensive care, survival improved, yet doctors still saw that timing mattered: in the “acute infectious” form, early symptoms of acquired purpura fulminans could appear within hours of sepsis; in the “post‑infectious” form, skin findings might emerge days to weeks after recovery from an illness like chickenpox. These clinical patterns, documented across decades, helped shape modern treatment—rapid antibiotics for infection, careful support of blood pressure and organ function, and targeted clotting factor replacement when needed.
Advances in blood testing in the late 20th century clarified that many people with acquired purpura fulminans have profoundly reduced levels of natural anticoagulants in the bloodstream, especially protein C, during the acute phase. This insight linked the visible skin damage to a surge of clotting within tiny vessels and guided the development of protein C replacement strategies in selected cases. In recent decades, knowledge has built on a long tradition of observation, with researchers refining supportive care and exploring how inflammation, toxins from bacteria, and immune responses combine to trigger the condition.
Despite evolving definitions, the core story has stayed consistent: a severe systemic illness can tip the body’s clot‑and‑bleed balance, leading to rapidly spreading skin purpura and tissue injury. Knowing the condition’s history underscores why fast recognition and coordinated care are so important today, and why follow‑up after recovery includes checking for lingering clotting imbalances and supporting skin healing and rehabilitation.